Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited Fundamental Analysis
Genor Biopharma Holdings Limited (6998.HK) shows weak financial fundamentals with a PE ratio of 63.48, profit margin of 8.99%, and ROE of 1.79%. The company generates $0.2B in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 38.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6998.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6998.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate6998.HK shows balanced valuation metrics.
Growth Score
Moderate6998.HK shows steady but slowing expansion.
Financial Health Score
Excellent6998.HK maintains a strong and stable balance sheet.
Profitability Score
Weak6998.HK struggles to sustain strong margins.
Key Financial Metrics
Is 6998.HK Expensive or Cheap?
P/E Ratio
6998.HK trades at 63.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 6998.HK's PEG of 0.51 indicates potential undervaluation.
Price to Book
The market values Genor Biopharma Holdings Limited at 1.16 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 228.15 times EBITDA. This signals the market has high growth expectations.
How Well Does 6998.HK Make Money?
Net Profit Margin
For every $100 in sales, Genor Biopharma Holdings Limited keeps $8.99 as profit after all expenses.
Operating Margin
Core operations generate -3.65 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.79 in profit for every $100 of shareholder equity.
ROA
Genor Biopharma Holdings Limited generates $1.52 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genor Biopharma Holdings Limited generates limited operating cash flow of $-32.58M, signaling weaker underlying cash strength.
Free Cash Flow
Genor Biopharma Holdings Limited generates weak or negative free cash flow of $-33.08M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.06 in free cash annually.
FCF Yield
6998.HK converts -2.55% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
63.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.75
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.93
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How 6998.HK Stacks Against Its Sector Peers
| Metric | 6998.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 63.48 | 28.31 | Worse (Expensive) |
| ROE | 1.79% | 699.00% | Weak |
| Net Margin | 8.99% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 4.93 | 2775.16 | Strong Liquidity |
| ROA | 1.52% | -14469.00% (disorted) | Weak |
6998.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genor Biopharma Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1381.67%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
90.81%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-3.38%
Industry Style: Defensive, Growth, Innovation
Declining